Immunohistochemical characterization of neoplastic cells of breast origin (original) (raw)
Related papers
Immunohistochemical markers in the identification of metastatic breast cancer
Breast cancer research and treatment, 1992
A panel of nine monoclonal and polyclonal antibodies were tested regarding specificity for metastatic breast cancer. A hundred metastatic tumors were stained, 50 of breast origin and 50 of other origins. Antibodies used were anti-alpha-lactalbumin, anti-lactoferrin, anti-casein, E29 (Dako-EMA), anti-secretory component, anti-gross cystic disease fluid protein (GCDFP15), BRST1, BRST2, and MC5. Analyses of the results were performed using chi-square and logistic regression. Positivity for MC5, BRST1, BRST2, lactoferrin, EMA, and GCDFP15 was significantly higher in tumors of breast origin than in others (p less than 0.05). Analyses of the whole panel indicated that GCDEP15 and MC5 were the best markers for identification of breast cancer metastases. When both were positive (58% of breast origin cases), the predicted probability of breast origin was 98%, compared to only 5% when both were negative. Comparison of anti-GCDFP15 with BRST2, a monoclonal antibody against the same protein, sh...
Annals of the New York Academy of Sciences, 2006
The detection of circulating tumor cells in the peripheral blood (pB) of breast cancer (BC) patients might become an important factor for the prognosis of BC patients. Sensitive molecular techniques, primarily based upon the reverse-transcriptase polymerase chain reaction (RT-PCR), have been developed using the expression of tissue-and/or tumor-specific genes as a marker for the presence of tumor cells.
2021
Background: Breast carcinoma is the most common malignancy in female worldwide, leading cause of death in women.immunohistochemistry plays a very important role in the prognostication and treatment determination of breast carcinoma patients. Objective: To analyze the immunohistochemical markers in invasive carcinoma of breast and to correlate the expression of hormonal receptors with age of the patient, tumor size, histological grade and lymph node metastasis.Materials and method: The study was conducted on 88 infiltrating ductal breast carcinoma sample in a tertiary care hospital of Southern Assam for a period of two year (January2018- December 2019). Data including age, tumor size, and histologic grade and lymph node status retrieved from pathology department. Chi- square was used to determine the statistical significance between ER/PR status HER2/neu status along with their correlation with various clinicopathological parametres with respect to infiltrating ductal breast carcinom...
Evaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors
Journal of Laboratory Physicians
Introduction Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest to identify a better biomarker, we studied mammaglobin (MAM) in patients with breast cancer and benign breast tumors. Aim To evaluate serum mammaglobin in breast cancer patients and compare it with benign breast tumor patients and healthy controls. To compare it with existing biomarkers serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3). Materials and methods: This is a cross-sectional, case–control study of 77 subjects, of which 27 were breast cancer patients, 20 benign breast tumor patients, and 30 healthy controls. Serum CEA and CA15–3 were estimated by electrochemiluminescence immunoassay (ECLIA) and mammaglobin (MAM) by enzyme-linked immunosorbent assay (ELISA). Results Mamm...
How We Use Immunohistochemistry to Arrive at a Diagnosis in Breast Lesions
Indian Journal of Medical and Paediatric Oncology, 2022
Immunohistochemistry (IHC) is an essential tool available to pathologists for facilitating diagnosis and as well as guiding the prognosis of breast lesions. Newer markers are increasingly being added to the pathologists' armamentarium. However, the selection and interpretation of the IHC markers should be judicious. In light of an appropriate morphological assessment, they should complement each other and produce accurate reports. We have briefly outlined here the immunohistochemical approach used in the diagnosis and management of breast cancers at our tertiary care cancer center.
The mammographic correlations of a new immunohistochemical classification of invasive breast cancer
Clinical Radiology, 2008
Recent protein expression profiling of breast cancer has identified specific subtypes with clinical, biological, and therapeutic implications. The aim of this study was to identify the mammographic correlates of these novel molecular classes of invasive breast cancer. MATERIALS AND METHODS: The mammographic findings of 415 patients with operable breast cancer were correlated with the previously described protein expression classes identified by our group using immunohistochemical (IHC) assessment of a large series of breast cancer cases prepared as tissue microarrays (TMAs). Twenty-five proteins of known relevance in breast cancer were assessed, including hormone receptors, HER-2 status, basal and luminal markers, p53 expression, and E-cadherin. RESULTS: The mammographic background pattern and proportion of lesions that were mammographically occult were similar in all groups. Groups characterized by luminal and hormone receptor positivity had significantly more spiculate lesions at mammography. Groups characterized by HER-2 overexpression, basal characteristics, and E-cadherin positivity had a significantly higher proportion of ill-defined masses. These findings were independent of histological grade. CONCLUSION: The mammographic features of breast cancer show significant correlation with molecular classes of invasive breast cancer identified by protein expression IHC analysis. The biological reasons for the findings and implications of these regarding imaging protocols require further study and may provide mechanisms for improvement of detection of these lesions.
International Surgery Journal, 2022
Background: Breast cancer is a systemic disease which has different biological subtypes with vast natural history, clinical presentation, various pathological types and molecular features which has impact on prognostic profile and outcome. Present study aims to evaluate correlation of receptor status (ER, PR and HER 2neu) with other tumor characteristics. Methods: The present study was a prospective observational study of 50 breast cancer patients and was conducted from January 2020 to June 2021 in surgical unit of the department of general surgery at MDM hospital attached with Dr. S. N. medical college, Jodhpur, Rajasthan. Results: Most common age group was 41-50 years in 38% cases. Majority of patients were females (49, 98%). The 88% cases had invasive duct carcinoma. ER, PR and HER 2neu positivity had statistically significant correlation with age (p<0.0001), histological grade (p<0.0001) and tumor size (p=0.04). HER 2neu had statistically significant negative correlation with ER and PR (p<0.05). Conclusions: Immunohistochemistry (IHC) markers (ER, PR, HER 2neu) are positively correlated with increasing age, tumor size, tumor grade and positive axillary lymph nodes, also there is statistically significant correlation between HER 2neu overexpression and hormone receptor (ER, PR) negativity in study population.
Mammaglobin: as a diagnostic marker for breast cancer
The expression of mammaglobin gene is predicted to be highly specific in breast cancer. The role of mammaglobin expression as a prognostic and therapeutic tool in breast cancer is widely accepted. The aim of this study was to investigate immunohistochemical expression of mammaglobin, and to determine the correlations with clinicopathological parameters. In the present study, immunohistochemical analysis of two hundred breast carcinoma patients was performed. The immunohistochemical reaction was scored based on the percentage of positive tumor cells. The positive expression rate of mammaglobin biomarker was observed in 69% of breast cancer patients. Tumor grade was found to be significantly associated with the Expression of mammaglobin (p=0.0017). Maximum patients (45%) were observed with tumor size 2-4.9 cm. No statistically significant association was observed among mammaglobin expression, tumor size, lymph node status and histological types. In conclusion, we suggested mammaglobin gene as excellent candidate for a novel and clinically useful breast tumor marker and help in management of breast cancer patients.